Reverb Therapeutics

Reverb Therapeutics is a biotechnology company harnessing the body’s natural immune system and cytokine signalling to treat life-threatening diseases. Its novel antibody-based Amplify•R™ platform amplifies and redirects endogenous cytokines to tissues of interest for the potential treatment of cancer, autoimmune conditions and other diseases.

“We are excited to have the backing of this standout group of investors as we advance the Amplify•R platform. The Amplify•R platform has broad potential across many cytokines. With this funding, we will take our lead IL-15 bispecific program to the candidate stage and will develop additional bispecific programs spanning other cytokines and additional cellular targets.” 

— David de Graaf, Ph.D, CEO of Reverb Therapeutics 

Established
2023

Aligned investment theme
Elevating inclusive communities

Purpose
To develop precision medicines for life-threatening diseases

InBC commitment amount
$3 million

Year invested
2024